Previous Close | 6.40 |
Open | 6.40 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 6.40 - 6.40 |
52 Week Range | 5.00 - 6.45 |
Volume | |
Avg. Volume | 3,543 |
Market Cap | 5.383B |
Beta (5Y Monthly) | 0.49 |
PE Ratio (TTM) | 18.82 |
EPS (TTM) | 0.34 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AKESF
Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparing Cadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with chemotherapy in the first-line treatment for patients with PD-L1 negative (PD-L1 TPS<1%) non-small cell lung cancer (NSCLC) (NCT05990127).
Akeso (9926.HK) announced that the results of a phase II clinical trial for PD-1/CTLA-4 bispecific antibody(cadonilimab)combined with standard treatment (chemotherapy +/- bevacizumab) as first-line treatment for recurrent/metastatic cervical cancer had been published in the official journal of the American Association for Cancer Research (AACR), Clinical Cancer Research, with an impact factor of 11.5.
Summit Therapeutics Inc. (NASDAQ:SMMT) Q4 2023 Earnings Call Transcript February 20, 2024 Summit Therapeutics Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to Summit’s Fourth Quarter and Year End 2023 Earnings Call. [Operator Instructions] Please […]